---
title: 'Scientist II / Senior Scientist, ADME at Immunome, Inc.'
canonical: 'https://feeny.ai/job/scientist-ii-senior-scientist-adme-immunome-inc-bothell-washington-s9z30n12w0jf'
type: 'job'
last_seen: '2026-09-05'
---

# Scientist II / Senior Scientist, ADME at Immunome, Inc.

- **Company:** Immunome, Inc.
- **Location:** Bothell Washington, United States
- **Compensation:** $150k–$204k
- **Posted:** 2026-08-24
- **Last confirmed live:** 2026-09-05
- **Apply:** https://job-boards.greenhouse.io/immunomeinc/jobs/5400017008

## Job description

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Position Overview

The Scientist II / Senior Scientist, ADME will contribute to the design and execution of nonclinical pharmacokinetics/PKPD/ADME strategies to support oncology drug candidates from discovery through development. This role will partner closely with cross-functional teams to deliver high-quality data that informs decision-making and regulatory submissions. Reporting to the Executive Director, Head of ADME, the Scientist II will work on multiple modalities, with a strong emphasis on ADC programs.

## Responsibilities

- Perform modeling and simulation, analyze PKPD and PK/TK data, and provide clear interpretation to inform program decisions.
- Design and execute stage-appropriate PKPD and ADME studies to support candidate selection, clinical development, and regulatory submissions.
- Collaborate with cross-functional teams to ensure integration of ADME considerations into program strategy and timelines.
- Participate in Translational Sciences and Development team activities, contributing scientific expertise in ADME.
- Represent the ADME function at internal and external meetings, in collaboration with senior scientists, communicating timelines, data, and implications effectively.
- Maintain awareness of evolving best practices and regulatory expectations in ADME sciences.

## Qualifications

- PhD in a relevant discipline with 0–3 years of industry experience in ADC PKPD and ADME, or MS with 5+ years relevant industry experience.
- Experience with ADCs required; additional experience with small molecules, monoclonal antibodies, or other modalities preferred.
- Hands-on expertise in PKPD modeling, PK/TK analysis, and study design.
- Knowledge of both non-regulated and regulated bioanalysis.

Knowledge and Skills

- Strong problem-solving skills with the ability to manage multiple projects in a fast-paced environment.
- Excellent communication skills, with the ability to present complex scientific data clearly to diverse audiences.
- Collaborative approach with the ability to work across disciplines to achieve program goals.

Level and compensation will be commensurate with relevant experience. Washington State Pay Range $149,930—$203,961 USD

E/E/O

Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

E-Verify

Immunome, Inc. is a participant in E-Verify. Please review the following notices: [E-Verify Participation Poster](https://immunome.box.com/s/bopxukipfidxjscs4bjxt75f90bvpppk) | https://immunome.box.com/s/r51g9subw1wqni9xkutbl6up635sjr8e | https://immunome.box.com/s/r3ekbimwh988my9vzl76tnlbg60zvh9u.

## About Immunome, Inc.

## Company Overview
- **One-liner**: Immunome is a clinical-stage oncology company developing first-in-class and best-in-class targeted cancer therapies, with a primary focus on antibody-drug conjugates (ADCs).
- **Entity Type**: Public (Nasdaq: IMNM)
- **Headquarters**: Bothell, Washington, United States
- **Founded**: The company was formed through a merger of Morphimmune and Immunome in October 2023.
- **Founders**: The company is led by Clay Siegall, Ph.D. (Chairman, CEO, and President), who co-founded Seagen. The original Immunome entity was founded earlier, but the current company structure dates to the 2023 merger.

## Core Business
- Primary industry/industries: Biotechnology, Oncology, Drug Discovery & Development
- Target customers: Patients with cancer, healthcare providers, and clinical trial sites. The company is a B2B/B2C entity in the healthcare and life sciences space.
- Mission or purpose statement: "Our mission is to improve outcomes for cancer patients by advancing and expanding a portfolio of first-in-class and best-in-class therapeutic candidates." [immunome.com](https://immunome.com/)

## Products & Services
- **Varegacestat (formerly AL102)**: A late-clinical stage gamma secretase inhibitor for the treatment of desmoid tumors. The company submitted a New Drug Application (NDA) to the U.S. FDA in April 2026. [investors.immunome.com](https://investors.immunome.com/)
- **IM-1021**: A ROR1-targeted antibody-drug conjugate (ADC) currently in a Phase 1 trial.
- **IM-3050**: A FAP-targeted radioligand which received IND clearance in Q1 2025.
- **Preclinical ADC Pipeline (IM-1617, IM-1340, IM-1335)**: ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 had its first patient dosed in a Phase 1 trial in June 2026. [investors.immunome.com](https://investors.immunome.com/)

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the search results. As a public company, this fluctuates. (Check recent filings for current data).
- **Key Metric**: The company is pre-revenue (clinical-stage) and has raised significant capital. Since the 2023 merger, CEO Clay Siegall has raised $355 million in equity financings. [immunome.com](https://immunome.com/about/)
- **Notable Investors/Partners**: The company is publicly traded. Key leadership previously worked at Seagen (acquired by Pfizer for $43 billion).
- **Growth Signals**: The company is rapidly advancing its pipeline. Key milestones include the NDA submission for varegacestat, first patient dosed for IM-1617, and positive Phase 3 data presented at ASCO 2026. The company currently lists 32 open positions on its careers page, indicating strong hiring momentum. [job-boards.greenhouse.io](http://job-boards.greenhouse.io/immunomeinc)

## Competitive Advantages
- **World-Class Leadership**: The executive team, led by Seagen co-founder Clay Siegall, has deep experience in designing, developing, and commercializing blockbuster ADCs (ADCETRIS, PADCEV, TIVDAK, TUKYSA). [immunome.com](https://immunome.com/about/)
- **Proprietary ADC Platform**: A systematic, data-driven process for optimizing antibodies, linkers, and payloads to create differentiated ADCs. [immunome.com](https://immunome.com/)
- **Near-Term Catalyst**: The NDA submission for varegacestat provides a potential near-term commercial opportunity.
- **Strong Financial Backing**: Raised $355M in equity since the merger, providing a solid runway for pipeline advancement.

## Strategic Focus
- **Advancing the Pipeline**: The primary focus is on executing clinical trials for varegacestat (Phase 3), IM-1021 (Phase 1), and IM-3050 (Phase 1), and advancing preclinical ADCs into the clinic.
- **Regulatory Filing**: Successfully navigating the FDA NDA submission and potential approval for varegacestat.
- **Discovery & Expansion**: Using their ADC discovery platform to generate new candidates and identify and acquire targeted oncology assets to expand the portfolio. [immunome.com](https://immunome.com/about/)

## Why Work Here
- **Mission-Driven**: The work directly impacts the lives of cancer patients, with a stated goal of developing transformative therapies. [immunome.com](https://immunome.com/about/)
- **High-Impact Team**: Opportunity to work with "some of the brightest and most experienced minds in ADC development," including leaders who have brought multiple drugs to market. [immunome.com](https://immunome.com/careers/)
- **Growth Stage**: With 32 open roles, the company is in a rapid growth phase, offering significant career advancement opportunities. [job-boards.greenhouse.io](http://job-boards.greenhouse.io/immunomeinc)
- **Comprehensive Benefits**: Includes 100% company-paid medical premiums for employees, a 401(k) with employer match, paid parental leave, and a week-long winter break. [immunome.com](https://immunome.com/careers/)
- **Location & Culture**: Based in Bothell, WA. The company describes a culture of "innovative, collaborative environment where employees are empowered to do their best work." [immunome.com](https://immunome.com/careers/)

## Sources
1. [Immunome Official Website](https://immunome.com/)
2. [Immunome About Page](https://immunome.com/about/)
3. [Immunome Investor Relations](https://investors.immunome.com/)
4. [Immunome Careers Page](https://immunome.com/careers/)
5. [Immunome Jobs on Greenhouse](http://job-boards.greenhouse.io/immunomeinc)

## Other roles at Immunome, Inc.

- [Senior Manager, Clinical Project Management (Project Delivery)](https://feeny.ai/job/senior-manager-clinical-project-management-project-delivery-immunome-inc-4qv8cbmwxyhp) — Bothell Washington, United States
- [Manager, External Manufacturing Operations](https://feeny.ai/job/manager-external-manufacturing-operations-immunome-inc-bothell-washington-344kbygcy4af) — Bothell Washington, United States
- [Associate Director, Clinical Contracts Counsel](https://feeny.ai/job/associate-director-clinical-contracts-counsel-immunome-inc-united-states-e0ftbdn2a6w8) — United States
- [Director / Senior Director, External Manufacturing Operations](https://feeny.ai/job/director-senior-director-external-manufacturing-operations-immunome-inc-bothell-rkeyxhs88kwn) — Bothell Washington, United States
- [Senior Contracts Manager](https://feeny.ai/job/senior-contracts-manager-immunome-inc-bothell-washington-3bmwb4ke189c) — Bothell Washington, United States
- [Senior Oncology Account Manager – Anticipated Opening (Product Launch)](https://feeny.ai/job/senior-oncology-account-manager-anticipated-opening-product-launch-immunome-inc-fc5qsz533qa0) — United States
- [Contract: Senior Recruiting Coordinator](https://feeny.ai/job/contract-senior-recruiting-coordinator-immunome-inc-bothell-washington-vw8zg43s3rjf) — Bothell Washington, United States
- [Principal Scientist, Analytical Development and QC, Small Molecule](https://feeny.ai/job/principal-scientist-analytical-development-and-qc-small-molecule-immunome-inc-c2et009d2yat) — Bothell Washington, United States
- [Associate Director / Director, Clinical Science](https://feeny.ai/job/associate-director-director-clinical-science-immunome-inc-bothell-washington-494qmvx9sfw1) — Bothell Washington, United States
- [Principal Scientist, Chemical Development](https://feeny.ai/job/principal-scientist-chemical-development-immunome-inc-bothell-washington-rckdg8s8tj7r) — Bothell Washington, United States